&nbsp;

Drugs Used:

ribociclib ,

fulvestrant

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

ABEMLETR

Cancer Type:

Breast

Intent: Adjuvant, Palliative

Funding:

Exceptional Access Program

abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria

ODB - General Benefit

letrozole

Drugs Used:

abemaciclib,

letrozole

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

ABEMANAS

Cancer Type:

Breast

Intent: Adjuvant, Palliative

Funding:

Exceptional Access Program

ODB - General Benefit

anastrozole

Drugs Used:

abemaciclib,

anastrozole

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

LORL

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

lorlatinib - For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.

Drugs Used:

lorlatinib

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

AXIT+PEMB

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

aXitinib - In combination with pembrolizumab for first-line advanced or metastatic renal cell carcinoma

New Drug Funding Program

Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma

Drugs Used:

aXitinib,

pembrolizumab

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

VENE+OBIN

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

New Drug Funding Program

Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia

Exceptional Access Program

venetoclax - In Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia, based on criteria

Drugs Used:

oBINutuzumab,

venetoclax

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

LENV

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

Exceptional Access Program

lenvatinib - For the treatment of unresectable advanced hepatocellular carcinoma according to clinical criteria

Drugs Used:

lenvatinib

Quick Link(s):

Regimen Monograph

Mar 2023

Regimen

DARO

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

darolutamide - For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC), based on criteria

Drugs Used:

darolutamide

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

AZCTVENE

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Palliative

Funding:

New Drug Funding Program

Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia

Drugs Used:

azaCITIDine,

venetoclax

Quick Link(s):

Regimen Monograph

Aug 2022

Regimen

DEXAPOMA+ISAT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

New Drug Funding Program

Isatuximab - In Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Exceptional Access Program

pomalidomide - In combination with isatuximab and dexamethasone for relapsed or refractory multiple myeloma, according to specific criteria

Drugs Used:

Quick Link(s):

Regimen Monograph

Feb 2024

Regimen

NIRP

Cancer Type:

Gynecologic,

Ovary

Intent: Adjuvant, Palliative

Funding:

Exceptional Access Program

niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria

Drugs Used:

niraparib